Regression and Eradication of Triple-Negative Breast Carcinoma in 4T1 Mouse Model by Combination Immunotherapies.

Nahar, Saifun; Huang, Yue; Nagy, Bethany A; Zebala, John A; Maeda, Dean Y; Rudloff, Udo; Oppenheim, Joost J; Yang, De

Nahar, Saifun; Huang, Yue; Nagy, Bethany A; Zebala, John A; Maeda, Dean Y; Rudloff, Udo; Oppenheim, Joost J; Yang, De.

Afiliación

Nahar S; Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, MD 21702, USA.
Huang Y; Rare Tumor Initiative, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
Nagy BA; Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, MD 21702, USA.
Zebala JA; Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, MD 21702, USA.
Maeda DY; Syntrix Pharmaceuticals, Auburn, WA 98001, USA.
Rudloff U; Syntrix Pharmaceuticals, Auburn, WA 98001, USA.
Oppenheim JJ; Rare Tumor Initiative, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
Yang; Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, MD 21702, USA.

Cancers (Basel) ; 15(8)2023 Apr 19.

Article en En | MEDLINE | ID: mdl-37190294

Palabras clave

4T1; FSL-1; HMGN1; ICB; R848; SX682; TNCB; alarmin; cancer therapy; immunotherapy

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Cancers (Basel) Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google